As LOXL1-AS1 promotes cell proliferation and migration in medulloblastoma via regulating the PI3K/AKT pathway, any compound or reagent targeting LOXL1-AS1 and consequently inhibiting the PI3K/AKT pathway might serve as a promising therapeutic strategy for the treatment of medulloblastoma. Here, LOXL1 is linked to medulloblastoma.